

CERTIFICATION OF HAND-DELIVERY

I hereby certify that this paper is being hand-delivered to the Patent and Trademark Office  
on the date shown below.

ATTIA SIDDIQUI

Type Name of Person Signing Certificate

Attia

Signature

5-6-02

Date

*Coff*

Attorney Docket No.: P32151C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Craig, et al.

May 6, 2002

Serial No.: 09/469,902

Group Art Unit No.: 1625

Filed: December 22, 1999

Examiner: C. Chang

For: Novel Compounds

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
TECH CENTER 1600/2300  
02 MAY -6 PM 1:49

RE-SUBMISSION OF AN INFORMATION DISCLOSURE STATEMENT

Applicants reference the telephonic message left with the undersigned attorney on or about May 2, 2002, which indicated that the IDS and references submitted in the above-referenced application (dated January 18, 2002) could not be located. In order to expedite the prosecution of this application, submitted herewith is a re-submission of the previously filed PTO Form 1449, IDS and references.

Also submitted herewith is a copy of the return receipt post card, dated January 18, 2002. This post card is stamped by the US PTO as an acknowledgement of receipt of the items listed thereon.

Serial No.: 09/469,902  
Group Art Unit No.: 1625

- 2 -

Please charge any fees under 37 CFR § 1.16 or §1.17 which may be required by this paper to Deposit Account No.: 19-2570.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Wayne J. Dustman", with a horizontal line extending from the end of the signature.

Wayne J. Dustman  
Attorney for Applicants  
Registration No.: 33,870

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5023  
Facsimile (610) 270-5090  
n:\wjd\ptoltrs\IP32151IDS2Resub.doc

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE  
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON

JANUARY 18, 2002

*Dr. Ramez J. G. G. G.*  
ATTORNEY FOR APPLICANT

*January 18, 2002*  
DATE

RECEIVED  
TECH CENTER 1600/2900  
02 MAY -6 PM 1:49

Attorney Docket No.: P32151C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Craig, et al. January 18, 2002  
Serial No.: 09/469,902 Group Art Unit No.: 1625  
Filed: December 22, 1999 Examiner: C. Chang  
For: "NOVEL COMPOUNDS"

Assistant Commissioner for Patents  
Washington, D.C. 20231

FILING OF AN INFORMATION DISCLOSURE STATEMENT


The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular document is or discloses effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed.

These documents are copies of litigation pleadings for Civil Action No.: 1:00CV01179, pending in the United States District Court for the Middle District of North Carolina and, in part, relate to United States Patent No. 6,063,927 (the parent of the subject application). Whether or not MPEP § 2001.06(c), which deals with the duty of disclosure and the materiality of information in related litigation, applies to the present application and pending claims, in an abundance of caution, Applicants wish to provide the Office with these documents which disclose various allegations and defenses regarding the patents involved.

In citing these documents, Applicants wish to direct attention to paragraph 5, section (b), of the Joint Stipulated Protective Order (reference CI), which states that confidential information, i.e. that covered by the protective order, may only be disclosed to in-house counsel "who are not involved in the prosecution of patents/applications relating to paroxetine." The undersigned attorney, being involved in the prosecution of applications relating to paroxetine, has not been provided with confidential information as referred to in the Protective Order, if such confidential information exist. Therefore, the documents cited herewith do not contain any such confidential information, if such confidential information exist.

Please charge any fees under 37 CFR § 1.16 or §1.17 which may be required by this paper to Deposit Account No.: 19-2570.

Respectfully submitted,



Wayne J. Dustman  
Attorney for Applicants  
Registration No.: 33,870

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5023  
Facsimile (610) 270-5090  
n:\wjd\ptolirs\p32151IDS2.doc